

beta-Aminoarteether Biochemical

beta-Aminoarteether

CATALOG #
AAA227590


PRODUCT SYNONYMS

beta-Aminoarteether; beta-Aminoarteether biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	133162-24-0
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	beta-Aminoarteether (SM934; 1-10 mg/kg; oral administration; dailiy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. beta-Aminoarteether treatment promotes the IL-10 production of macrophages from NZB/W F1 mice[1]. Animal Model: Female NZB/W F1 mice (Six and half months old)[1]. Dosage: 1 mg/kg, 3mg/kg, and 10 mg/kg. Administration: Oral administration; dailiy; for 3 months. Result: Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
DBCO-C2-SulfoNHS ester, CAS 1803279-86-8



Structure
DBCO-C2-SulfoNHS ester, CAS 1803279-86-8

ADDITIONAL INFORMATION

Related Product Information for beta-Aminoarteether biochemical	beta-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. beta-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases.
References	1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

